[8-K] INmune Bio Inc. Common stock Reports Material Event

Rhea-AI Filing Summary

INmune Bio (NASDAQ:INMB) filed an 8-K announcing it will host a conference call on June 30, 2025 at 8:00 a.m. ET to present top-line data from its Phase 2 MINDFuL trial in early Alzheimer’s disease.

The filing:

• Attaches the related press release as Exhibit 99.1
• Provides no efficacy or safety figures; full results will be disclosed during the call
• Contains no changes to financial statements or guidance

The scheduling of a data read-out signals analysis completion and sets a near-term catalyst for shareholders, but the document itself does not alter the company’s financial position.

Positive

• Announcement of June 30, 2025 release of top-line Phase 2 MINDFuL Alzheimer’s data, a potential value-defining clinical milestone

Negative

• None.

Insights

Biotech Analyst

TL;DR: Date set for pivotal Phase 2 read-out, no results yet

The 8-K confirms management will reveal top-line outcomes from the double-blind Phase 2 MINDFuL study in early Alzheimer’s on June 30. While no data are supplied, scheduling the call implies data lock and analysis are complete, a prerequisite for disclosure. The study’s primary cognitive endpoint and safety profile will dictate progression to Phase 3 or partnership potential. Investors now have a clear catalyst date; however, without numerical efficacy signals the filing itself neither adds nor subtracts value. Maintaining a wait-and-see stance until results emerge is prudent.

Portfolio Manager

TL;DR: Near-term catalyst identified; risk-reward unchanged until data

The disclosure sets an information overhang removal deadline. With four trading days’ notice, volatility may rise as market participants reposition ahead of the read-out. Because the filing contains no financial metrics, valuation remains binary and contingent on forthcoming efficacy. Historical Alzheimer’s trials often create outsized share-price swings; expect derivatives activity and hedging to intensify. Overall impact today is neutral, but the event could quickly become transformative once data are known.

false 0001711754 0001711754 2025-06-26 2025-06-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 26, 2025

INMUNE BIO INC.

(Exact name of registrant as specified in charter)

Nevada		001-38793		47-5205835
(State or other jurisdiction		(Commission File Number)		(IRS Employer
of incorporation)				Identification No.)

225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432

(Address of Principal Executive Offices) (Zip Code)

(858) 964 3720

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per shares		INMB		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On June 26, 2025, INmune Bio Inc. issued a press release announcing it will host a conference call on Monday, June 30, 2025, at 8:00 a.m., Eastern Time to present top line data from the Phase 2 MINDFuL trial in early Alzheimer’s disease. A copy of the press release is attached herewith as Exhibit 99.1.

Item 9.01 Financial statements and Exhibits

(d) Exhibits.

99.1		Press Release dated June 26, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INMUNE BIO INC.
Date: June 26, 2025	By:	/s/ David Moss
		David Moss
		Chief Financial Officer

2

FAQ

When will INMB release the Phase 2 MINDFuL trial top-line results?

INMB will present the data during a conference call on June 30, 2025 at 8:00 a.m. ET.

What Alzheimer’s study is INMB discussing in its June 26 8-K?

The filing concerns the Phase 2 MINDFuL trial evaluating INmune Bio’s therapy in early Alzheimer’s disease.

How can investors access INMB’s June 30 2025 conference call?

Dial-in and webcast details are provided in the press release attached as Exhibit 99.1 to the 8-K.

Did INMB include any efficacy or safety data in this 8-K?

No. The filing only announces the upcoming presentation; no numerical trial results are disclosed.

Does the 8-K change INMB’s financial guidance or outlook?

The document contains no financial statements or guidance updates; outlook remains unchanged until data are released.

Why is the MINDFuL top-line read-out important for INMB shareholders?

Phase 2 outcomes will inform progression to Phase 3 and could significantly impact valuation and strategic options.